On Monday, Pfizer and BioNTech announced they have asked the FDA to grant an emergency use authorization for their new version of a Covid-19 vaccine that’s been adapted to be specific to the BA.4/BA.5 versions of the Omicron variant.
The worst of the pandemic is behind us, experts told Forbes, in part because the first two years provided valuable tools for the continued fight against both Covid and future disease epidemics.
The company’s new public health initiative aims to work with middle- and low-income countries to combat diseases, while working with scientists worldwide to develop vaccines for the next potentially deadly outbreak.